1.58
+0.07(+4.64%)
Currency In USD
Address
900 Middlefield Road
Redwood City, CA 94063
United States of America
Phone
650 980 9099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
April 16, 2021
| Name | Title | Pay | Year Born |
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer & Director | 56,500 | 1950 |
| Mr. Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer & Director | 489,604 | 1963 |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer | 492,250 | N/A |
| Dr. Stephan Morris M.D. | Chief Development Officer | 0 | N/A |
| Mr. Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property | 0 | N/A |
| Ms. Naomi Cretcher | Chief People Officer | 0 | N/A |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | 0 | 1970 |
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts | 0 | N/A |
| Mr. Heow Tan | Chief Technology & Quality Officer | 0 | 1959 |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.